Healthcare services group Uniphar said the business performed in line with its expectations in the first half at both a gross profit and EBITDA level.
In a trading update today, Uniphar reported organic gross profit growth of about 7%.
Breaking down its divisions, it said its Uniphar Pharma unit delivered strong double-digit organic gross profit growth during the period and remains on track to deliver double-digit organic gross profit growth for the full year.
Its Uniphar Medtech reported low single digit organic gross profit growth during the half, compared to a very strong previous year comparator, and expectations of high single-digit organic gross profit growth for the full year remain unchanged.
Meanwhile, its Supply Chain & Retail business delivered low single-digit organic gross profit growth during the half and remains on track to deliver low single-digit organic gross profit growth for the full year.
Uniphar said it has entered the second half of this year with strong trading momentum and remains confident in delivering on its current year earnings per share expectations.
It added that merger and acqusitions continue to play an important role in its growth strategy, adding that it maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance its growth potential.
Ger Rabbette, Uniphar's group chief executive, said that Uniphar has had a great first half, achieving significant organic gross profit growth.
"We are well-positioned to continue this progress into the second half and meet our growth objectives for each of our three divisions for the full year. Our focus remains on reaching our target of €200m EBITDA in the medium term," he added.
